Stoke Therapeutics, Inc. (STOK)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Stoke Therapeutics, Inc. (STOK)

Company Performance

Current Price

as of Oct 16, 2024

$13.03

P/E Ratio

N/A

Market Cap

$686M

Description

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Metrics

Overview

HQBedford, MA
SectorHealth Technology
IndustryBiotechnology
TickerSTOK
Price$13.03+2.68%

Trading Information

Market Cap$686.00M
Float78.56%
Average Daily Volume (1m)689,211
Average Daily Volume (3m)564,679
EPS-$2.19

Company

Revenue$15.16M
Rev Growth (1yr)N/A
Net Income-$25.70M
Gross Margin77.02%
EBITDA Margin-584.39%
EBITDA-$28.23M

EV$477.17M
EV/Revenue31.48
P/EN/A
P/S47.94
P/B2.81

Documents

Factset Street Account

Stoke Therapeutics to present data from Dravet syndrome clinical program at the American Epilepsy Society 2023 Annual Meeting ($4.17, 0.00) (2023-11-21T13:03:30Z)

Stoke Therapeutics reports Q3 EPS ($0.55) vs FactSet ($0.63) [8 est, ($0.67)-(0.59)] ($4.31, 0.00) (2023-11-07T12:10:21Z)

Stoke Therapeutics presents data from multiple studies of children and adolescents with Dravet syndrome at AES annual meeting ($3.79, 0.00) (2023-12-01T14:02:56Z)